FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] Though the company has posted steady growth in its top and bottom lines, its tiny post-IPO paid-up equity capital indicates longer gestation for migration to the mainboard. Based on FY22 earnings, its IPO is priced aggressively. This pricy issue may be skipped. Read detail review...
EP Biocomposites IPO Reviews, analysis and views by popular members. Read EP Biocomposites Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 2 | 1 |
% | 0.00 | 0.00 | 66.67 | 33.33 |
Member | Review |
---|---|
Ipoyes |
Neutral Ok sme September 2, 2022 11:36:11 AM |
GOEL STOCK LINK |
Neutral FULLY PRICED, RISKY IPO. YOU CAN APPLY FOR LISTING GAIN . September 1, 2022 4:28:17 PM |
Bull Morris |
Avoid I do not think, to get listing gain in this company. The company is very old but it has launched IPO now, may be due to some internal issues. I want expert opinion whether to apply or not ...? August 26, 2022 3:36:41 PM |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|